Compare IXHL & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IXHL | ONMD |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.4M | 29.9M |
| IPO Year | 2024 | 2021 |
| Metric | IXHL | ONMD |
|---|---|---|
| Price | $1.96 | $5.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 69.0K | 26.9K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.33 |
| EPS | N/A | ★ N/A |
| Revenue | $12,000.00 | ★ $1,359,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 111.35 |
| 52 Week Low | $0.16 | $0.63 |
| 52 Week High | $6.39 | $115.00 |
| Indicator | IXHL | ONMD |
|---|---|---|
| Relative Strength Index (RSI) | 21.19 | 41.46 |
| Support Level | $0.20 | $3.86 |
| Resistance Level | $3.82 | $39.25 |
| Average True Range (ATR) | 0.19 | 0.53 |
| MACD | -0.04 | 0.81 |
| Stochastic Oscillator | 6.02 | 63.64 |
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.